MA26671A1 - COMPOSITION PHARMACEUTIQUE POUVANT eTRE ADMINISTRÉE PAR VOIE ORALE CONTENANT UN INHIBITEUR DE LIPASE GASTRO-INTESTINALE, UN (OU PLUSIEURS) ADDITIF(S) DU GROUPE CONSTITUE PAR LES ÉPAISSISSANTS, ET ÉMULSIFIANTS DE QUALITÉ ALIMENTAIRE MÉDIOCREMENT DIGESTIBLES, MÉDIOCREMENT FERMENTABLES, HYDROPHILES ET OU HYDROCOLLOiDAUX ET DES EXCIPIENTS AUXILIAIRES - Google Patents

COMPOSITION PHARMACEUTIQUE POUVANT eTRE ADMINISTRÉE PAR VOIE ORALE CONTENANT UN INHIBITEUR DE LIPASE GASTRO-INTESTINALE, UN (OU PLUSIEURS) ADDITIF(S) DU GROUPE CONSTITUE PAR LES ÉPAISSISSANTS, ET ÉMULSIFIANTS DE QUALITÉ ALIMENTAIRE MÉDIOCREMENT DIGESTIBLES, MÉDIOCREMENT FERMENTABLES, HYDROPHILES ET OU HYDROCOLLOiDAUX ET DES EXCIPIENTS AUXILIAIRES

Info

Publication number
MA26671A1
MA26671A1 MA25725A MA25725A MA26671A1 MA 26671 A1 MA26671 A1 MA 26671A1 MA 25725 A MA25725 A MA 25725A MA 25725 A MA25725 A MA 25725A MA 26671 A1 MA26671 A1 MA 26671A1
Authority
MA
Morocco
Prior art keywords
hyrodiocredely
hyrodiocredriately
digiously
digious
médiocre
Prior art date
Application number
MA25725A
Other languages
English (en)
Inventor
Manuela Hug
Hans-Peter Maerki
Marcel Meier
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA26671A1 publication Critical patent/MA26671A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • General Preparation And Processing Of Foods (AREA)
MA25725A 1998-08-14 1999-08-11 COMPOSITION PHARMACEUTIQUE POUVANT eTRE ADMINISTRÉE PAR VOIE ORALE CONTENANT UN INHIBITEUR DE LIPASE GASTRO-INTESTINALE, UN (OU PLUSIEURS) ADDITIF(S) DU GROUPE CONSTITUE PAR LES ÉPAISSISSANTS, ET ÉMULSIFIANTS DE QUALITÉ ALIMENTAIRE MÉDIOCREMENT DIGESTIBLES, MÉDIOCREMENT FERMENTABLES, HYDROPHILES ET OU HYDROCOLLOiDAUX ET DES EXCIPIENTS AUXILIAIRES MA26671A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98115311 1998-08-14
EP99109516 1999-05-12

Publications (1)

Publication Number Publication Date
MA26671A1 true MA26671A1 (fr) 2004-12-20

Family

ID=26149537

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25725A MA26671A1 (fr) 1998-08-14 1999-08-11 COMPOSITION PHARMACEUTIQUE POUVANT eTRE ADMINISTRÉE PAR VOIE ORALE CONTENANT UN INHIBITEUR DE LIPASE GASTRO-INTESTINALE, UN (OU PLUSIEURS) ADDITIF(S) DU GROUPE CONSTITUE PAR LES ÉPAISSISSANTS, ET ÉMULSIFIANTS DE QUALITÉ ALIMENTAIRE MÉDIOCREMENT DIGESTIBLES, MÉDIOCREMENT FERMENTABLES, HYDROPHILES ET OU HYDROCOLLOiDAUX ET DES EXCIPIENTS AUXILIAIRES

Country Status (19)

Country Link
US (1) US6358522B1 (fr)
EP (1) EP1105122B1 (fr)
JP (1) JP3774118B2 (fr)
KR (1) KR20010079635A (fr)
CN (1) CN1170534C (fr)
AR (1) AR035001A1 (fr)
AT (1) ATE293970T1 (fr)
AU (1) AU761351B2 (fr)
BR (1) BR9912980B1 (fr)
CA (1) CA2340056C (fr)
CO (1) CO5130009A1 (fr)
DE (1) DE69924999T2 (fr)
DK (1) DK1105122T3 (fr)
ES (1) ES2242413T3 (fr)
MA (1) MA26671A1 (fr)
PE (1) PE20000953A1 (fr)
PT (1) PT1105122E (fr)
TR (1) TR200100471T2 (fr)
WO (1) WO2000009122A1 (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6299868B1 (en) 1999-07-14 2001-10-09 Geltex Pharmaceuticals, Inc. Fat-binding polymers
US7048917B1 (en) 1998-01-09 2006-05-23 Genzyme Corporation Fat-binding polymers
US6264937B1 (en) * 1998-01-09 2001-07-24 Geltex Pharmaceuticals, Inc. Fat-binding polymers
NZ510311A (en) 1998-09-08 2003-08-29 Smithkline Beecham Corp Lipstatin derivative - soluble fiber tablets
AR025587A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
AR025609A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
EP1132389A1 (fr) 2000-03-06 2001-09-12 Vernalis Research Limited Nouveaux dérivés de l'azaindole pour le traitement de l'obésité
HU229550B1 (en) * 2000-06-27 2014-01-28 Hoffmann La Roche Method for preparing compositions
DK1307263T3 (da) * 2000-07-28 2005-08-22 Hoffmann La Roche Hidtil ukendt anvendelse af lipaseinhibitorer
PT1307264E (pt) * 2000-07-28 2005-02-28 Hoffmann La Roche Nova composicao farmaceutica
WO2002011719A2 (fr) 2000-08-09 2002-02-14 F. Hoffmann-La Roche Ag Utilisation d'inhibiteurs de lipase
AR038762A1 (es) 2000-10-16 2005-01-26 Hoffmann La Roche Derivados de indolina, un proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion y el uso de dichos derivados para la fabricacion de un medicamento
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
KR100539143B1 (ko) 2000-12-27 2005-12-26 에프. 호프만-라 로슈 아게 인돌 유도체 및 그의 5-ｈｔ2ｂ 및 5-ｈｔ2ｃ 수용체리간드로서의 용도
GB0106177D0 (en) 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
AU2002338896B2 (en) 2001-05-21 2006-04-27 F.Hoffman-La Roche Ag Quinoline derivatives as ligands for the neuropeptide Y receptor
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US6730319B2 (en) * 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
US7041280B2 (en) * 2001-06-29 2006-05-09 Genzyme Corporation Aryl boronate functionalized polymers for treating obesity
US7049345B2 (en) * 2001-06-29 2006-05-23 Genzyme Corporation Fat-binding polymers
US6787558B2 (en) 2001-09-28 2004-09-07 Hoffmann-La Roche Inc. Quinoline derivatives
GB0202015D0 (en) 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
EP1474145B1 (fr) 2002-02-04 2008-04-23 F. Hoffmann-La Roche Ag Derives de quinoline en tant qu'antagonistes du neuropeptide (npy)
WO2003072577A1 (fr) 2002-02-28 2003-09-04 F.Hoffmann-La Roche Ag Derives thiazoles utilises comme antagonistes du recepteur npy
JP4234017B2 (ja) * 2002-04-26 2009-03-04 エフ．ホフマン−ラ ロシュ アーゲー リパーゼ阻害薬及びグルコマンナンを含む医薬組成物
CN1665791A (zh) 2002-07-05 2005-09-07 霍夫曼-拉罗奇有限公司 喹唑啉衍生物
MXPA05001328A (es) 2002-08-07 2005-04-28 Hoffmann La Roche Derivados de tiazol.
CN100577660C (zh) 2002-09-12 2010-01-06 霍夫曼-拉罗奇有限公司 作为ppar激动剂用于治疗糖尿病的n-取代-1h-吲哚-5-丙酸化合物
WO2004048371A1 (fr) 2002-11-25 2004-06-10 F.Hoffmann-La Roche Ag Derives d'indolyle
US8372430B2 (en) * 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
GB0314967D0 (en) 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
CN100393718C (zh) 2003-08-12 2008-06-11 霍夫曼-拉罗奇有限公司 作为npy拮抗剂的噻唑衍生物
BRPI0413500A (pt) 2003-08-12 2006-10-10 Hoffmann La Roche compostos, processos para a sua preparação, composição farmacêutica que compreende os mesmos, utilização de um composto, métodos para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade
AU2006243243B2 (en) 2005-05-03 2009-05-14 F. Hoffmann-La Roche Ag Tetracyclic azapyrazinoindolines as 5-HT2 ligands
JP5044398B2 (ja) 2005-06-09 2012-10-10 武田薬品工業株式会社 固形製剤
DE602006006712D1 (de) 2005-08-18 2009-06-18 Hoffmann La Roche Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
KR20080076987A (ko) 2005-11-30 2008-08-20 에프. 호프만-라 로슈 아게 5-치환된 인돌-2-카복스아미드 유도체
CN101316838B (zh) 2005-11-30 2013-01-30 霍夫曼-拉罗奇有限公司 用作h3调节剂的1,1-二氧代-硫代吗啉基吲哚基甲酮衍生物
KR101124156B1 (ko) 2005-11-30 2012-03-23 에프. 호프만-라 로슈 아게 1,5-치환된 인돌-2-일 아마이드 유도체
CA2631128A1 (fr) 2005-12-09 2007-06-14 F. Hoffmann-La Roche Ag Derives d'amides tricycliques utiles pour le traitement de l'obesite
JP2009519290A (ja) 2005-12-15 2009-05-14 エフ．ホフマン−ラ ロシュ アーゲー ピロロ［２，３−ｃ］ピリジン誘導体
DE602006014305D1 (de) 2005-12-16 2010-06-24 Hoffmann La Roche Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
US7432255B2 (en) 2006-05-16 2008-10-07 Hoffmann-La Roche Inc. 1H-indol-5-yl-piperazin-1-yl-methanone derivatives
CN101448820A (zh) 2006-05-30 2009-06-03 霍夫曼-拉罗奇有限公司 哌啶基嘧啶衍生物
US7514433B2 (en) 2006-08-03 2009-04-07 Hoffmann-La Roche Inc. 1H-indole-6-yl-piperazin-1-yl-methanone derivatives
US20080146559A1 (en) 2006-12-08 2008-06-19 Li Chen 4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives
US7862688B2 (en) * 2007-05-16 2011-01-04 Buckman Laboratories International, Inc. Methods to control organic contaminants in fibers
EP2183237A1 (fr) 2007-07-25 2010-05-12 F. Hoffmann-Roche AG Dérivés d'amide d'acide benzofurane- et benzo[b]thiophène-2-carboxylique et leur utilisation comme modulateurs du récepteur h3 de l'histamine
WO2009044380A2 (fr) 2007-10-05 2009-04-09 Ranbaxy Laboratories Limited Formulations contenant des particules d'orlistat à dimension de particule contrôlée
EP2219614A1 (fr) * 2007-10-15 2010-08-25 Inventis DDS Pvt Limited Composition pharmaceutique d'orlistat
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
US8309107B2 (en) 2008-10-06 2012-11-13 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
GB201122213D0 (en) * 2011-12-23 2012-02-01 Norgine Bv Compositions
CN104546768B (zh) * 2014-12-30 2017-06-16 重庆植恩药业有限公司 含有脂肪酶抑制剂的咀嚼片组合物及其制备方法
EP3471709A1 (fr) * 2016-06-17 2019-04-24 The Procter & Gamble Company Composition molle à mâcher comprenant du psyllium
CN112220831A (zh) * 2020-08-07 2021-01-15 天津盛实百草中药科技有限公司 圆苞车前子壳粉在缓解奥利司他副作用中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4005195A (en) * 1976-02-12 1977-01-25 The Procter & Gamble Company Compositions for treating hypercholesterolemia
CA1247547A (fr) 1983-06-22 1988-12-28 Paul Hadvary Derives de leucine
US5294451A (en) * 1991-03-29 1994-03-15 Curtice-Burns, Inc. Fat substitute compositions having reduced laxative effects
CA2098167C (fr) * 1992-06-24 2006-12-19 Dorothea Isler Aliments pour humains et animaux contenant un inhibiteur de la lipase
TW381025B (en) * 1993-08-05 2000-02-01 Hoffmann La Roche Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
JPH09252746A (ja) * 1996-03-22 1997-09-30 Nippon Kankyo Yakuhin Kk 栄養補助食品
JP4202439B2 (ja) * 1996-10-01 2008-12-24 江崎グリコ株式会社 フラボノイド可溶化法、その糖転移法及び高濃度フラボノイド溶液
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions

Also Published As

Publication number Publication date
BR9912980B1 (pt) 2013-10-22
PT1105122E (pt) 2005-08-31
CO5130009A1 (es) 2002-02-27
BR9912980A (pt) 2001-05-08
CN1312713A (zh) 2001-09-12
PE20000953A1 (es) 2000-09-26
DE69924999T2 (de) 2006-05-04
DK1105122T3 (da) 2005-08-08
TR200100471T2 (tr) 2001-07-23
AU761351B2 (en) 2003-06-05
ATE293970T1 (de) 2005-05-15
CA2340056A1 (fr) 2000-02-24
JP2002522491A (ja) 2002-07-23
WO2000009122A1 (fr) 2000-02-24
EP1105122B1 (fr) 2005-04-27
ES2242413T3 (es) 2005-11-01
DE69924999D1 (de) 2005-06-02
AR035001A1 (es) 2004-04-14
KR20010079635A (ko) 2001-08-22
EP1105122A1 (fr) 2001-06-13
CN1170534C (zh) 2004-10-13
CA2340056C (fr) 2007-01-09
JP3774118B2 (ja) 2006-05-10
AU5418599A (en) 2000-03-06
US6358522B1 (en) 2002-03-19

Similar Documents

Publication Publication Date Title
MA26671A1 (fr) COMPOSITION PHARMACEUTIQUE POUVANT eTRE ADMINISTRÉE PAR VOIE ORALE CONTENANT UN INHIBITEUR DE LIPASE GASTRO-INTESTINALE, UN (OU PLUSIEURS) ADDITIF(S) DU GROUPE CONSTITUE PAR LES ÉPAISSISSANTS, ET ÉMULSIFIANTS DE QUALITÉ ALIMENTAIRE MÉDIOCREMENT DIGESTIBLES, MÉDIOCREMENT FERMENTABLES, HYDROPHILES ET OU HYDROCOLLOiDAUX ET DES EXCIPIENTS AUXILIAIRES
CA2340052A1 (fr) Compositions pharmaceutiques contenant des inhibiteurs de lipases et du chitosane
NO2013019I2 (no) Aliskiren eller et farmasøytisk akseptabelt salt derav, og hydroklortiazid eller et farmasøytisk akseptabelt salt derav.
NO993519L (no) Fenofibrat farmasöytisk blanding som har höy biotilgjengelighet og fremgangsmÕte for fremstilling av den
MA25284A1 (fr) Composition antioxydante, y compris l'acide de l'acetylene, l-carnitine qui ameliore l'utilisation metabolique du glucose.
BR9908438A (pt) Tabletes de desintegração rápida
DZ3165A1 (fr) Composition alimentaire ou pharmaceutique utiliseepour prevenir ou traiter l'hyperoxalurie.
ES2091737T3 (es) Formulaciones farmaceuticas de fluoxetina.
BG103425A (en) Pharmaceutical composition
AR038207A1 (es) Composicion farmaceutica dispersable oralmente de agomelatina
BR0007294A (pt) Formulações farmacêuticas aperfeiçoadas
WO2005007137A8 (fr) Comprimés contenant de l'ambroxol
HUP0201631A2 (hu) Alkalikus szfingomielinázt tartalmazó dietetikus készítmények, ételkiegészítők és gyógyászati termékek
HUP0002644A2 (hu) Aldóz reduktáz inhibítort és ACE inhibitort tartalmazó gyógyászati készítmények
DZ2564A1 (fr) Compositions pharmaceutiques pour le traitement dudiabète sucre et d'états associés.
JPS51128438A (en) An antibacterial drug against fish diseases
DZ3103A1 (fr) Nouvelles pyrazolo Ä4,3-EÜdiazépines substituées, compositions pharmaceutiques les contenant, utili sation à titre de médicament et procédés pour leurs préparation.
CA2378724A1 (fr) Composition pour prevenir et traiter les affections et les maladies du rein
ATE224195T1 (de) Glucocorticoide zur behandlung von glomerulonephitis
FR2668697B1 (fr) Dissecteur, notamment pour chirurgie endoscopique.
WO2001022917A8 (fr) Compositions effervescentes comportant du nimesulide
ATE357931T1 (de) Mittel zur prävention/behandlung entzündlicher darmerkrankungen
CA2420056A1 (fr) 1-amino-alkylcyclohexanes en tant qu'agents trypanocidaux
ITRM950421A0 (it) 17-idrossiimminoalchil e 17-idrossiimminometilalchenil ciclopentaperidrofenantreni attivi sul sistema cardiovascolare, procedimento per la loro preaparazione e composizioni farmaceutiche che li contengono.
ECSP993103A (es) Composiciones farmaceuticas